Nonetheless, the construct used in these models does not reflect the underlying pathological processes in PD; dopaminergic degeneration, as measured by cell loss and α-synuclein immunoreactivity in post mortem PD brains, does not occur until the middle stages of PD (Braak stage 3; [209]). This evidence concerns the gene SNCA and Parkinson disease.